Roche: receives CE mark for its cobas solution

(CercleFinance.com) - Roche announced today that it has received CE marking for its cobas® Mass Spec solution, comprising the cobas® i 601 analyzer and the first four-assay Ionify® reagent pack for steroid hormones.


CE marking is the first step in the global launch of the cobas Mass Spec solution, which uses an in-house innovation to bring automated clinical mass spectrometry testing to the market.

Following launch, the cobas Mass Spec solution will offer a menu of over 60 analytes for testing steroid hormones, vitamin D metabolites, immunosuppressive drugs (ISD), therapeutic drug monitoring (TDM) and drug testing (DAT).

' The cobas Mass Spec solution will revolutionize the field of clinical diagnostics', said Matt Sause, CEO of Roche Diagnostics.

' This solution would make fully standardized clinical mass spectrometry more widely available and improve patient care worldwide.'

Copyright (c) 2024 CercleFinance.com. All rights reserved.